- Email: [email protected]
Conference Program: 42nd Annual Conference of the European Teratology
Reproductive Toxicology 48 (2014) 6–8
Contents lists available at ScienceDirect
Reproductive Toxicology journal homepage: www.elsevier.com/locate/reprotox
Conference Program
Conference Programme: 42nd Annual Conference of the European Teratology
Monday 1 September ETS Council Meeting 1
09.00-13.00 14.30-14.40
Education course: 14.40-15.25 Molecular Pathways in Embryology 15.25-16.10 Sponsored by Covance Chairs: Gerhard Weinbauer, 16.10-16.40 Michael Ohara 16.40-17.15
Introduction
Gerhard Weinbauer, Covance, Germany
E-1 Signalling pathways in embryology - Nobue Itasaki, University College Dublin, foundation Ireland E-2 Techniques for discovering pathways that lead to dysmorphogenesis
Nicola Powles-Glover, AstraZeneca, UK.
Coffee E-3 Signatures for predictive toxicology
Thomas Knudsen, US EPA, USA
Young Scientists’ Happy Hour
18.00-19.00
Welcome Reception
19.00-21.30
With light refreshments
08.30-08.45
ETS President – Nina Hallmark
08.45-09.00
Introduction
09.00-09.40
S1-1 Imaging and morphology in reproductive toxicology - progress to date and future Julian French, Morphology Consulting Ltd, UK directions
09.40-10.10
Coffee
10.10-10.50
S1-2 Use of imaging technologies in birth defects research, a clinical perspective
Philip Loquet, Augustinus Hospital Antwerp, Belgium
10.50-11.30
S1-3 Fetal skeletal imaging with micro-CT
Colena Johnson, Merck, USA
President’s Award Lecture Chair: Nina Hallmark
11.30-12.15
Dragons, deities and double headed monsters. A personal look at the history and understand- Sheila Tesh, Tesh Consultants International, UK ing of conjoined twins.
Lunch
12.15-13.15
Tuesday 2 September Welcome address
Symposium 1 Imaging Techniques Chairs: Luc De Schaepdrijver, Edward Marsden
Symposium 2 Adverse Outcome Pathways – future for DART testing Sponsored by WIL Research Chairs: Manon Beekhuijzen, Aldert Piersma
Luc De Schaepdrijver, Janssen, Belgium
13.15-13.30
S2-0 Introduction of adverse outcome pathways (AOPs)
13.30-14.10
S2-1 Adverse outcome pathway based battery approaches in an alternative strategy for Aldert Piersma, RIVM, The Netherlands reproductive toxicity testing
14.10-14.50
S2-2 Identifying key events in AOPs for embryonic disruption by using computational toxicology
14.50-15.30
S2-3 Using information from adverse outcome Mark Cronin, John Moores University pathways and integrated testing strategies to Liverpool, UK inform on DART endpoints
15.30-16.00
Coffee
S0890-6238/$ – see front matter http://dx.doi.org/10.1016/j.reprotox.2014.07.063
Manon Beekhuijzen, WIL Research, The Netherlands
Thomas Knudsen, US EPA, NC, USA
Conference Programme / Reproductive Toxicology 48 (2014) 6–8
ETS/TS Exchange Lecture 16.00-16.20 Is Lack of Mandatory Folic Acid Fortification Public 16.20-16.40 Health Malpractice? Chairs: Sue Makris, Paul 16.40-17.10 Barrow Poster session
17.10-19.00
Past Presidents informal dinner
19.00 -
7
T-1 The impact of spina bifida on individuals, families and society
Margo L. Whiteford, NHS Greater Glasgow and Clyde, UK
T-2 Accelerating the pace of preventing spina bifida F and anencephaly F
Godfrey P. Oakley Jr., Emory University, USA
Discussion
Invitation only
Wednesday 3 September
Symposium 3 Developmental Neurotoxicology and Behaviour Sponsored by Charles River Chairs: Geertje Lewin, Ulla Hass
Free communications Chairs: Nina Hallmark, Alberto Mantovani
08.30-09.10
S3-1 Sensitivity of behavioral testing compared to other endpoints (endocrine disruption)
Ulla Hass, Technical University of Denmark
09.10-09.50
S3-2 Effect of inflammation on central nervous system development and vulnerability
Carina Mallard, University of Gothenburg, Sweden
09.50-10.30
S3-3 How can academic research studies fill important information gaps in regulatory risk Anna Beronius, University of Stockholm, assessment? – The example of developmental Sweden neurotoxicity of bisphenol A
10.30-10.50
Coffee
10.50-11.30
S3-4 Assessment of CNS Safety in Juvenile Animals
Jim Ridings, GSK, UK
11.30-11.45
F-1 Persisting oxidative stress and elevated HIF1Ð in the offspring of Cohen diabetic rats fed a high sucrose low copper diet
Zivanit Ergaz–Shaltiel, Hebrew University Hadassah Medical School, Israel
11.45-12.00
F-2 Perinatal exposure to DOTC (di-N-octyltin dichloride) affects brain development. A study in rats using MRI (magnetic resonance imaging), [18F]FDG brain PET and genome wide gene expression profiling
Didima M. de Groot, TNO, The Netherlands
12.00-12.15
F-3 Perinatal bisphenol A (BPA) exposure causes non-monotonic dose-response relationships on some reproductive and neurobehavioural endpoints
Marta Axelstad, National Food Institute, Denmark
12.15-12.30
F-4 The European recommendations for primary prevention of congenital anomalies
Alberto Mantovani, Istituto Superiore di Sanità, Italy
Lunch
12.30-13.30
Elsevier Award Lecture
13.30-14.10
A-1 Evaluation of an alternative in vitro test battery for detecting reproductive toxicants
Aldert Piersma, RIVM, The Netherlands
Symposium 4 The Role of Primary Cilia in Normal and Abnormal Development Supported in part by March of Dimes Foundation Grant No.4-FY14-477. Chairs: Shay Giles, Nicola Powles-Glover
14.10-14.25
Introduction
Shay Giles, University College Dublin, Ireland
14.25-15.05
S4-1 The primary cilium as an integration Jill Helms, Stanford University, USA center for Hedgehog and Wnt signaling
15.05-15.45
S4-2 Primary cilia and teratological effects in the central nervous system
15.45-16.05
Coffee
16.05-16.45
S4-3 Cilia and ciliopathies: classic examples linking phenotype and genotype
AGM
16.45-18.15
ETS members only
ETS Gala Dinner
19.30-late
Kerry L. Tucker, University of Heidelberg, Germany
Nicola Powles-Glover, AstraZeneca, UK
8
Conference Programme / Reproductive Toxicology 48 (2014) 6–8
Thursday 4 September Presentation of ETS meeting 09.00-09.10 2015
Manon Beekhuijzen, ETS Incoming Vice President, WIL Research, The Netherlands
09.10-09.25
F-5 Temperatures of 32.5°C and above impact zebrafish embryonic development
09.25-09.40
F-6 Developmental toxicity assessment of tanezumab, an anti-nerve growth factor Christopher J. Bowman, Pfizer, USA monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis)
09.40-09.50
Introduction
Jane Stewart, AstraZeneca, UK
09.50-10.10
S5-1 What fetal exposure/outcome could occur from drugs in semen? – Studies with metronidazole and thalidomide
Julia Hui, Celgene, USA
10.10-10.30
S5-2 Assessment of fetal exposure risk from seminal transfer of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model
Bill Breslin, Lilly, USA
10.30-11.00
Coffee
11.00-11.20
S5-3 Nonclinical investigation of maternal and fetal exposure to an IgG2 monoclonal antibody Graeme Moffat, Amgen, USA following biweekly vaginal administration throughout pregnancy
11.20-11.40
S5-4 Optical imaging to assess potential intravaginal embryo-fetal exposure
Bruce K Beyer, Sanofi, USA
11.40-12.00
S5-5 Regulatory concern for seminal drug transfer and exposure to untreated partners
Lutz Wiesner, Federal Institute for Drugs and Medical Devices, Germany
12.00-12.30
Questions and discussion
Farewell Address
12.30-12.40
Paul Barrow, incoming ETS President, Roche, Switzerland
ETS Council Meeting 2
13.00-15.30
Free communications
Symposium 5 Drugs in Semen Organised by ILSI/HESI Chair: Alan Hoberman
Casper Pype, University of Antwerp, Belgium
Contents lists available at ScienceDirect
Reproductive Toxicology journal homepage: www.elsevier.com/locate/reprotox
Conference Program
Conference Programme: 42nd Annual Conference of the European Teratology
Monday 1 September ETS Council Meeting 1
09.00-13.00 14.30-14.40
Education course: 14.40-15.25 Molecular Pathways in Embryology 15.25-16.10 Sponsored by Covance Chairs: Gerhard Weinbauer, 16.10-16.40 Michael Ohara 16.40-17.15
Introduction
Gerhard Weinbauer, Covance, Germany
E-1 Signalling pathways in embryology - Nobue Itasaki, University College Dublin, foundation Ireland E-2 Techniques for discovering pathways that lead to dysmorphogenesis
Nicola Powles-Glover, AstraZeneca, UK.
Coffee E-3 Signatures for predictive toxicology
Thomas Knudsen, US EPA, USA
Young Scientists’ Happy Hour
18.00-19.00
Welcome Reception
19.00-21.30
With light refreshments
08.30-08.45
ETS President – Nina Hallmark
08.45-09.00
Introduction
09.00-09.40
S1-1 Imaging and morphology in reproductive toxicology - progress to date and future Julian French, Morphology Consulting Ltd, UK directions
09.40-10.10
Coffee
10.10-10.50
S1-2 Use of imaging technologies in birth defects research, a clinical perspective
Philip Loquet, Augustinus Hospital Antwerp, Belgium
10.50-11.30
S1-3 Fetal skeletal imaging with micro-CT
Colena Johnson, Merck, USA
President’s Award Lecture Chair: Nina Hallmark
11.30-12.15
Dragons, deities and double headed monsters. A personal look at the history and understand- Sheila Tesh, Tesh Consultants International, UK ing of conjoined twins.
Lunch
12.15-13.15
Tuesday 2 September Welcome address
Symposium 1 Imaging Techniques Chairs: Luc De Schaepdrijver, Edward Marsden
Symposium 2 Adverse Outcome Pathways – future for DART testing Sponsored by WIL Research Chairs: Manon Beekhuijzen, Aldert Piersma
Luc De Schaepdrijver, Janssen, Belgium
13.15-13.30
S2-0 Introduction of adverse outcome pathways (AOPs)
13.30-14.10
S2-1 Adverse outcome pathway based battery approaches in an alternative strategy for Aldert Piersma, RIVM, The Netherlands reproductive toxicity testing
14.10-14.50
S2-2 Identifying key events in AOPs for embryonic disruption by using computational toxicology
14.50-15.30
S2-3 Using information from adverse outcome Mark Cronin, John Moores University pathways and integrated testing strategies to Liverpool, UK inform on DART endpoints
15.30-16.00
Coffee
S0890-6238/$ – see front matter http://dx.doi.org/10.1016/j.reprotox.2014.07.063
Manon Beekhuijzen, WIL Research, The Netherlands
Thomas Knudsen, US EPA, NC, USA
Conference Programme / Reproductive Toxicology 48 (2014) 6–8
ETS/TS Exchange Lecture 16.00-16.20 Is Lack of Mandatory Folic Acid Fortification Public 16.20-16.40 Health Malpractice? Chairs: Sue Makris, Paul 16.40-17.10 Barrow Poster session
17.10-19.00
Past Presidents informal dinner
19.00 -
7
T-1 The impact of spina bifida on individuals, families and society
Margo L. Whiteford, NHS Greater Glasgow and Clyde, UK
T-2 Accelerating the pace of preventing spina bifida F and anencephaly F
Godfrey P. Oakley Jr., Emory University, USA
Discussion
Invitation only
Wednesday 3 September
Symposium 3 Developmental Neurotoxicology and Behaviour Sponsored by Charles River Chairs: Geertje Lewin, Ulla Hass
Free communications Chairs: Nina Hallmark, Alberto Mantovani
08.30-09.10
S3-1 Sensitivity of behavioral testing compared to other endpoints (endocrine disruption)
Ulla Hass, Technical University of Denmark
09.10-09.50
S3-2 Effect of inflammation on central nervous system development and vulnerability
Carina Mallard, University of Gothenburg, Sweden
09.50-10.30
S3-3 How can academic research studies fill important information gaps in regulatory risk Anna Beronius, University of Stockholm, assessment? – The example of developmental Sweden neurotoxicity of bisphenol A
10.30-10.50
Coffee
10.50-11.30
S3-4 Assessment of CNS Safety in Juvenile Animals
Jim Ridings, GSK, UK
11.30-11.45
F-1 Persisting oxidative stress and elevated HIF1Ð in the offspring of Cohen diabetic rats fed a high sucrose low copper diet
Zivanit Ergaz–Shaltiel, Hebrew University Hadassah Medical School, Israel
11.45-12.00
F-2 Perinatal exposure to DOTC (di-N-octyltin dichloride) affects brain development. A study in rats using MRI (magnetic resonance imaging), [18F]FDG brain PET and genome wide gene expression profiling
Didima M. de Groot, TNO, The Netherlands
12.00-12.15
F-3 Perinatal bisphenol A (BPA) exposure causes non-monotonic dose-response relationships on some reproductive and neurobehavioural endpoints
Marta Axelstad, National Food Institute, Denmark
12.15-12.30
F-4 The European recommendations for primary prevention of congenital anomalies
Alberto Mantovani, Istituto Superiore di Sanità, Italy
Lunch
12.30-13.30
Elsevier Award Lecture
13.30-14.10
A-1 Evaluation of an alternative in vitro test battery for detecting reproductive toxicants
Aldert Piersma, RIVM, The Netherlands
Symposium 4 The Role of Primary Cilia in Normal and Abnormal Development Supported in part by March of Dimes Foundation Grant No.4-FY14-477. Chairs: Shay Giles, Nicola Powles-Glover
14.10-14.25
Introduction
Shay Giles, University College Dublin, Ireland
14.25-15.05
S4-1 The primary cilium as an integration Jill Helms, Stanford University, USA center for Hedgehog and Wnt signaling
15.05-15.45
S4-2 Primary cilia and teratological effects in the central nervous system
15.45-16.05
Coffee
16.05-16.45
S4-3 Cilia and ciliopathies: classic examples linking phenotype and genotype
AGM
16.45-18.15
ETS members only
ETS Gala Dinner
19.30-late
Kerry L. Tucker, University of Heidelberg, Germany
Nicola Powles-Glover, AstraZeneca, UK
8
Conference Programme / Reproductive Toxicology 48 (2014) 6–8
Thursday 4 September Presentation of ETS meeting 09.00-09.10 2015
Manon Beekhuijzen, ETS Incoming Vice President, WIL Research, The Netherlands
09.10-09.25
F-5 Temperatures of 32.5°C and above impact zebrafish embryonic development
09.25-09.40
F-6 Developmental toxicity assessment of tanezumab, an anti-nerve growth factor Christopher J. Bowman, Pfizer, USA monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis)
09.40-09.50
Introduction
Jane Stewart, AstraZeneca, UK
09.50-10.10
S5-1 What fetal exposure/outcome could occur from drugs in semen? – Studies with metronidazole and thalidomide
Julia Hui, Celgene, USA
10.10-10.30
S5-2 Assessment of fetal exposure risk from seminal transfer of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model
Bill Breslin, Lilly, USA
10.30-11.00
Coffee
11.00-11.20
S5-3 Nonclinical investigation of maternal and fetal exposure to an IgG2 monoclonal antibody Graeme Moffat, Amgen, USA following biweekly vaginal administration throughout pregnancy
11.20-11.40
S5-4 Optical imaging to assess potential intravaginal embryo-fetal exposure
Bruce K Beyer, Sanofi, USA
11.40-12.00
S5-5 Regulatory concern for seminal drug transfer and exposure to untreated partners
Lutz Wiesner, Federal Institute for Drugs and Medical Devices, Germany
12.00-12.30
Questions and discussion
Farewell Address
12.30-12.40
Paul Barrow, incoming ETS President, Roche, Switzerland
ETS Council Meeting 2
13.00-15.30
Free communications
Symposium 5 Drugs in Semen Organised by ILSI/HESI Chair: Alan Hoberman
Casper Pype, University of Antwerp, Belgium